code stringlengths 4 12 | description stringlengths 2 264 | codetype stringclasses 8
values | context stringlengths 160 15.5k |
|---|---|---|---|
95803 | PR ACTIGRAPHY TESTING RECORDING ANALYSIS I&R | HCPCS | Medications include – Stimulants (like Modafinil (Provigil) or Armodafinil (Nuvigil), Amphetamine-like stimulants, Methylphenidate (Aptensio XR, Concerta, and Ritalin), Sodium oxybate and other antidepressant drugs. Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulati... |
95783 | PR POLYSOM <6 YRS SLEEP W/CPAP/BILVL VENT 4/> PARAM | HCPCS | Medications include – Stimulants (like Modafinil (Provigil) or Armodafinil (Nuvigil), Amphetamine-like stimulants, Methylphenidate (Aptensio XR, Concerta, and Ritalin), Sodium oxybate and other antidepressant drugs. Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulati... |
95810 | Sleep study in sleep lab (6 years or older) | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95807 | Sleep study including heart rate and breathing attended by technician | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95811 | SLEEP STUDY W INTITIATION OF CPAP TX/VEN | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
G0400 | PR HOME SLEEP TEST/TYPE 4 PORTA | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95801 | Slp stdy unatnd w/anal | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95806 | Sleep study unatt&resp efft | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95805 | Sleep study, multiple trials | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95782 | PR POLYSOM <6 YRS SLEEP STAGE 4/> ADDL PARAM ATTND | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
G0398 | PR HOME SLEEP TEST/TYPE 2 PORTA | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
G0399 | PR HOME SLEEP TEST/TYPE 3 PORTA | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95800 | Slp stdy unattended | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95808 | PR POLYSOM ANY AGE SLEEP STAGE 1-3 ADDL PARAM ATTND | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95803 | PR ACTIGRAPHY TESTING RECORDING ANALYSIS I&R | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
95783 | PR POLYSOM <6 YRS SLEEP W/CPAP/BILVL VENT 4/> PARAM | HCPCS | Incorporating lifestyle adjustments such avoiding the intake of caffeine, alcohol and nicotine, regulating sleep schedules, establishing a normal exercise pattern and meal schedule and scheduling short naps (10-15 minutes in length) at regular intervals during the day may help reduce symptoms in the long-run. Allergy a... |
E0218 | Fluid circ cold pad w pump | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
E0236 | Pump for water circulating pad | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
E0218 | Fluid circ cold pad w pump | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY2/2001: Approved by Medical Policy Advisory Committee (MPAC), Code Reference section completed, HCPCS E0218 added
5/2/2002: Type of Service and Place of Service deleted
... |
E0236 | Pump for water circulating pad | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY2/2001: Approved by Medical Policy Advisory Committee (MPAC), Code Reference section completed, HCPCS E0218 added
5/2/2002: Type of Service and Place of Service deleted
... |
J9000 | INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
G0364 | HC BONE MARROW ASPIRATE & BIOPSY | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
J9999 | Not otherwise classified, antineoplastic drugs | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
38230 | PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
86812 | Immunologic analysis for autoimmune disease, A, B, or C, single antigen | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
86822 | Lymphocyte culture primed | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
38204 | PR MGMT RCP HEMATOP PROGENITOR CELL DONOR &ACQUISJ | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
G0355 | CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC | HCPCS | In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology mus... |
J9000 | INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
G0364 | HC BONE MARROW ASPIRATE & BIOPSY | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
J9999 | Not otherwise classified, antineoplastic drugs | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
38230 | PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
86812 | Immunologic analysis for autoimmune disease, A, B, or C, single antigen | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
86822 | Lymphocyte culture primed | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
38204 | PR MGMT RCP HEMATOP PROGENITOR CELL DONOR &ACQUISJ | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
G0355 | CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA... |
J9000 | INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
G0364 | HC BONE MARROW ASPIRATE & BIOPSY | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
J9999 | Not otherwise classified, antineoplastic drugs | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
38230 | PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
86812 | Immunologic analysis for autoimmune disease, A, B, or C, single antigen | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
86822 | Lymphocyte culture primed | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
38204 | PR MGMT RCP HEMATOP PROGENITOR CELL DONOR &ACQUISJ | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
G0355 | CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC | HCPCS | POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC)
6/25/2004: Code Reference section completed
11/18/2004: Review... |
86816 | HC HLA TYPING DR/DQ SINGLE AG | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86826 | Hla x-match noncytotoxc addl | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
S2140 | Cord blood harvesting for transplantation, allogeneic | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86821 | Lymphocyte culture mixed | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86813 | HC HLA TYPING; A, B, OR C, MULTIPLE ANTIGENS | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86822 | Lymphocyte culture primed | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86812 | Immunologic analysis for autoimmune disease, A, B, or C, single antigen | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86825 | X-MATCHAHG | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86817 | HC HLA TYPING; DR/DQ, MULTIPLE ANTIGENS | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
S2142 | Cord blood-derived stem-cell transplantation, allogeneic | HCPCS | Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140... |
86816 | HC HLA TYPING DR/DQ SINGLE AG | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
G0267 | Bone marrow or psc harvest | CPT | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
S2140 | Cord blood harvesting for transplantation, allogeneic | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
G0265 | Cryopresevation Freeze+stora | CPT | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
86813 | HC HLA TYPING; A, B, OR C, MULTIPLE ANTIGENS | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
86822 | Lymphocyte culture primed | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
86812 | Immunologic analysis for autoimmune disease, A, B, or C, single antigen | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
G0266 | Thawing + expansion froz cel | CPT | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
86821 | Lymphocyte culture mixed | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
86817 | HC HLA TYPING; DR/DQ, MULTIPLE ANTIGENS | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
S2142 | Cord blood-derived stem-cell transplantation, allogeneic | HCPCS | Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no... |
0240 | HC BH RESIDENTIAL FULL MONTH STAY | RC | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30240G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, OPEN APPROACH Reduced Intensity Medsurg | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30240G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, OPEN APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
0243 | All Inclusive Ancillary - Specialty | RC | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30240Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, OPEN APPROACH Reduced Intensity Medsurg | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30240Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, OPEN APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 03/21/2016: Policy description updated regarding FDA regulations. Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, a... |
0240 | HC BH RESIDENTIAL FULL MONTH STAY | RC | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30240G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, OPEN APPROACH Reduced Intensity Medsurg | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30240G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, OPEN APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
0243 | All Inclusive Ancillary - Specialty | RC | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30240Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, OPEN APPROACH Reduced Intensity Medsurg | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30240Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, OPEN APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Policy statements unchanged. 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8... |
0240 | HC BH RESIDENTIAL FULL MONTH STAY | RC | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30240G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, OPEN APPROACH Reduced Intensity Medsurg | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30240G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, OPEN APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
0243 | All Inclusive Ancillary - Specialty | RC | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30240Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, OPEN APPROACH Reduced Intensity Medsurg | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30240Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, OPEN APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | 05/25/2016: Policy number added. 09/30/2016: Code Reference section updated to add the following new ICD-10 procedure codes: 30240G2, 30243G2, 30240G3, 30243G3, 30240G4, 30243G4, 30240Y2, 30243Y2, 30240Y3, 30243Y3, 30240Y4, and 30243Y4. SOURCE(S)Blue Cross Blue Shield Association Policy # 8.01.28
CODE REFERENCEThis may... |
76536 | US THYROID | HCPCS | It signifies the professional component and can be billed only by a physician, a nurse practitioner or physician assistant. Face-to-face visits with the patient can be reported using the appropriate evaluation and management code. The device component for CGM is reported using HCPCS codes. Specifically assigned HCPCS c... |
76942 | US GUID NEEDLE PLCMNTPORTABLE | HCPCS | Face-to-face visits with the patient can be reported using the appropriate evaluation and management code. The device component for CGM is reported using HCPCS codes. Specifically assigned HCPCS codes help to establish credibility for the medical technology used and thereby reduce claim denials. Coding for Ultrasound E... |
76536 | US THYROID | HCPCS | Face-to-face visits with the patient can be reported using the appropriate evaluation and management code. The device component for CGM is reported using HCPCS codes. Specifically assigned HCPCS codes help to establish credibility for the medical technology used and thereby reduce claim denials. Coding for Ultrasound E... |
60100 | PR BIOPSY THYROID PERCUTANEOUS CORE NEEDLE | HCPCS | The device component for CGM is reported using HCPCS codes. Specifically assigned HCPCS codes help to establish credibility for the medical technology used and thereby reduce claim denials. Coding for Ultrasound Evaluation
Diagnostic ultrasound and associated ultrasound guided procedures performed by endocrinologists a... |
76942 | US GUID NEEDLE PLCMNTPORTABLE | HCPCS | The device component for CGM is reported using HCPCS codes. Specifically assigned HCPCS codes help to establish credibility for the medical technology used and thereby reduce claim denials. Coding for Ultrasound Evaluation
Diagnostic ultrasound and associated ultrasound guided procedures performed by endocrinologists a... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.